[Form 4] BioMarin Pharmaceuticals Inc Insider Trading Activity

Rhea-AI Filing Summary

BioMarin Pharmaceutical Inc. (BMRN) – Form 4

On 08/01/2025, director Ian T. Clark was awarded 7,000 restricted stock units (RSUs) of BioMarin common stock, recorded with transaction code “A” (acquisition). Because RSUs are granted by the company, the stated price is $0.00 and no open-market cash outlay occurred. Following the grant, Clark’s direct beneficial ownership stands at 7,000 shares; no indirect holdings or derivative positions were reported. The filing contains no sales, options, or additional equity instruments.

The transaction represents routine director equity compensation rather than an opportunistic purchase, but it modestly increases insider alignment with shareholders. No earnings data, guidance changes, or other material corporate events accompany this filing.

Positive

• Increased insider alignment: Director now holds 7,000 shares via RSUs, modestly tying compensation to shareholder value.

Negative

• No open-market purchase: RSU grant carries less conviction than a cash buy and is unlikely to signal valuation views.
• Immaterial size: ~$0.6 million value is negligible relative to BioMarin’s market capitalization, limiting market impact.

Insights

Insider Transactions Analyst

TL;DR: Routine 7k-share RSU grant to new director; minimal market impact.

The Form 4 discloses an automatic award of 7,000 RSUs to director Ian T. Clark. At a recent BMRN price near $90, the grant’s face value is roughly $0.6 million—immaterial versus BioMarin’s ~$17 billion market cap. Because RSUs vest over time and involve no cash purchase, the grant signals standard board compensation rather than a confidence-driven buy. No corresponding sales, derivatives, or 10b5-1 plan references alter the interpretation. Investors typically treat such grants as neutral; the filing mainly updates the public float and insider ownership ledger.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CLARK IAN T

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		A		7,000	A	$0(1)	7,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on August 1, 2025. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BioMarin (BMRN) shares did Ian T. Clark acquire?

The director received 7,000 restricted stock units on 08/01/2025.

Was the transaction an open-market purchase?

No. It was an equity grant from the company at a reported price of $0.00.

What is Ian T. Clark’s total direct holding after the grant?

He directly owns 7,000 BMRN shares; no indirect holdings were disclosed.

Does the filing mention any derivative securities or sales?

No derivative positions or dispositions were reported in Table II.

Is this Form 4 likely to affect BioMarin’s stock price?

Given the small, routine nature of the grant, the impact is expected to be minimal.